Repligen Corp has finished buying BioLife Sciences, which will no longer operate on its own.

Oct 6, 2026, 9:16 AM ETDealRead the original at SEC EDGAR

Neutral

Repligen completed the BioLife merger, paying BioLife owners cash and Repligen shares. The filing does not describe business gains from BioLife, so it does not change Repligen's outlook.

RGEN · Repligen Corporation

AI read · Neutral

The AI's read

The filing confirms the deal is complete, but it does not explain what BioLife adds to Repligen's sales or profits. Repligen paid with cash and shares, so the deal brings a payment and gives BioLife owners part ownership in Repligen. With no stated business gains to weigh against those costs, this filing alone does not change the company's outlook.

Get alerts for RGEN

Follow Repligen Corporation (RGEN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RGEN

Free on the App Store and Google Play, or on the web.